| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.34 | 8e-08 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.35 | 1e-07 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-06 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-06 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.28 | 1e-05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.19 | 0.002 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.005 |